Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average – Time to Sell?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.09 and traded as high as $3.86. Achieve Life Sciences shares last traded at $3.81, with a volume of 235,411 shares.

Achieve Life Sciences Trading Down 0.8%

The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.85. The company has a market cap of $132.15 million, a price-to-earnings ratio of -2.84 and a beta of 1.63. The company’s fifty day moving average price is $2.97 and its two-hundred day moving average price is $3.09.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37). Research analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Achieve Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Achieve Life Sciences in the fourth quarter valued at approximately $554,000. Tower Research Capital LLC TRC boosted its stake in Achieve Life Sciences by 185.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 4,905 shares during the last quarter. Northern Trust Corp boosted its position in shares of Achieve Life Sciences by 11.7% during the fourth quarter. Northern Trust Corp now owns 416,796 shares of the biopharmaceutical company’s stock worth $1,467,000 after purchasing an additional 43,682 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Achieve Life Sciences during the fourth quarter worth $49,000. Finally, Bank of America Corp DE boosted its position in shares of Achieve Life Sciences by 37.0% during the fourth quarter. Bank of America Corp DE now owns 36,168 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 9,760 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.